A LinkedIn post from Levee Medical highlights that UChicago Medicine and Dr. Abhinav Sidana have enrolled their first patient in the ARID II IDE pivotal trial. The update notes that this makes UChicago Medicine the 15th site to enroll a patient, indicating continued site activation and patient recruitment momentum for the study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the ARID II pivotal trial is evaluating the Voro® Urologic Scaffold and its impact on early and long-term continence following prostate surgery. For investors, advancing enrollment at multiple sites may signal progress toward generating clinical data that could support future regulatory review, adoption in post-prostatectomy care, and potential long-term revenue opportunities if outcomes are favorable.
The post also emphasizes appreciation for the clinical team at UChicago Medicine and frames the work as contributing to improved post-prostatectomy patient outcomes. While no timelines, financial details, or regulatory milestones are mentioned, the continued expansion of trial participation could enhance Levee Medical’s positioning in the urologic device segment if the Voro® scaffold demonstrates meaningful clinical benefit.